The Venture Codex Logo

The Venture Codex

Genomatica

4757 Nexus Center Dr, San Diego, California, 92121, United States

Overview

Genomatica leverages biology to remake everyday products and materials with reduced environmental impact. The company replaces widely used chemicals and materials traditionally derived from fossil fuels with plant-based alternatives. It has commercialized sustainable materials used in plastics, spandex and cosmetics, and is developing plant-based nylon, household cleaners and other products. Genomatica says its alternatives are cost-competitive, equivalent in performance and can reduce environmental impact by up to 93% compared to fossil-fuel based production. Led by CEO Christophe Schilling, the company aims to scale production across a range of industries and continue investing in new technologies to amplify the impact of sustainable materials. Genomatica recently raised funding (see deal memo) to support these plans. Genomatica is a San Diego, CA-based biotechnology company that develops bio-based process technologies to produce widely-used chemicals from alternative feedstocks. It has commercialized two processes: a biobased 1,4-butanediol (BDO) process used in biodegradable and compostable plastics and packaging, and a Brontide™ biobased butylene glycol process used in natural cosmetic and personal-care products. The company is also advancing a process to make 100% biobased nylon-6 for clothing and carpets. Genomatica partners with organism engineering firms such as Ginkgo Bioworks. The company raised $90M in equity financing to accelerate expansion of its product lines and strengthen its partnership with Ginkgo. The funds are intended to scale commercialization of existing processes and support development of new bio-based chemicals. Genomatica is a San Diego–based developer of process technologies that enable partners to produce intermediate and basic chemicals from renewable raw materials. Its core offering is economically attractive manufacturing processes intended to replace conventional petrochemical routes for chemical intermediates. The company raised $41.5 million in a Series D preferred stock financing. Management said the investment was made at a significant increase in valuation compared with a Series C-1 round announced in March 2011. New investor and partner Versalis participated alongside existing backers Alloy Ventures, Draper Fisher Jurvetson, Mohr Davidow Ventures, TPG Biotech, VantagePoint Capital Partners and Waste Management. Genomatica also withdrew a registration statement for a proposed IPO filed with the SEC on Aug. 23, 2011, saying the private financing was the most attractive option for the company and its shareholders. Genomatica develops chemicals from renewable feedstocks, converting a range of sugars into industrial molecules such as Bio-BDO. Bio-BDO is positioned to replace oil- or natural-gas-derived 1,4-butanediol in spandex, automotive plastics, running shoes and other applications. The company says Bio-BDO is made from renewable sugars and that its first commercial-scale plant will be fully operational in late 2013. Genomatica will use the new financing to bring Bio-BDO to mass market and to develop additional renewable chemicals. Financially, the company has raised $85 million in venture capital to date, including the latest $45 million round. The company is based in San Diego. Genomatica develops technologies to transform chemical production through bio-manufacturing. Its flagship process targets commercial-scale production of 1,4 butanediol (BDO), a building block for high-performance polymers, solvents and fine chemicals used in clothing, cars and electronics. The company plans to accelerate development and scale-up of that BDO process. It also intends to expand its pipeline to include additional large-market chemical targets produced from renewable feedstocks. Genomatica completed an initial $15M close of its Series C funding led by TPG Biotech, with participation from existing investors Mohr Davidow Ventures, Alloy Ventures and Draper Fisher Jurvetson. The new funds will be used to support commercialization and pipeline expansion.

Total raised
$310M
Funding rounds
5
Latest round
Series C
Latest activity
Jul 2021

Industries

  • Chemical Engineering
  • CleanTech
  • Manufacturing
  • Renewable Energy
Visit website

Recent funding

  1. Series C

    Jul 2021

    $118M

  2. Equity

    Oct 2018

    $90M

  3. Series D

    Aug 2012

    $42M

  4. Equity

    Mar 2011

    $45M

  5. Series C

    Mar 2010

    $15M

Team

  • Christophe Schilling

    Co-Founder & CEO

    LinkedIn
  • Tom McDonald

    Chief Financial Officer

    LinkedIn
  • Amy Buono

    Vice President, People & Culture

    LinkedIn
  • Bill Baum

    Executive Chairman and Chief Business Development Officer

    LinkedIn